Theravance Biopharma (NASDAQ:TBPH) Releases Earnings Results, Beats Expectations By $0.71 EPS

Theravance Biopharma (NASDAQ:TBPH) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.71, FiscalAI reports. The company had revenue of $45.89 million for the quarter, compared to the consensus estimate of $43.09 million. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%.

Theravance Biopharma Stock Up 1.3%

Shares of Theravance Biopharma stock traded up $0.18 during midday trading on Thursday, hitting $14.01. The company’s stock had a trading volume of 778,453 shares, compared to its average volume of 928,591. Theravance Biopharma has a 1-year low of $7.90 and a 1-year high of $21.03. The firm has a market capitalization of $709.89 million, a P/E ratio of 24.58 and a beta of 0.17. The stock has a 50-day simple moving average of $18.10 and a 200-day simple moving average of $16.84.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TBPH. BTIG Research dropped their price target on shares of Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. Wall Street Zen cut Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. B. Riley Financial restated a “neutral” rating and issued a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a research report on Wednesday, March 4th. Finally, Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Theravance Biopharma has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This represents a 11.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. AQR Capital Management LLC bought a new position in shares of Theravance Biopharma during the 1st quarter worth about $101,000. Jane Street Group LLC grew its position in Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after buying an additional 88,540 shares in the last quarter. Creative Planning acquired a new stake in Theravance Biopharma during the second quarter worth about $139,000. American Century Companies Inc. increased its stake in Theravance Biopharma by 6.8% during the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after acquiring an additional 5,794 shares during the period. Finally, Invesco Ltd. raised its holdings in Theravance Biopharma by 12.4% in the 2nd quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 2,789 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.